Immune to Cancer: The CRI Blog
-
FDA Approves Blood Test to Screen for Colon Cancer
People living with colorectal cancer, their families, caregivers, and doctors were given a glimmer of hope on… -
FDA approves EPKINLY® for relapsed or refractory follicular lymphoma
June 26, 2024, marked a milestone for patients suffering from follicular lymphoma. The FDA approved Genmab’s epcoritamab-bysp… -
CRI’s 5th Annual Wear White Luncheon Raises Over $40,000
On Thursday, June 20, 2024, the Cancer Research Institute (CRI) celebrated its fifth annual Wear White Luncheon,… -
Keytruda Receives 40th FDA Approval
This week marked a significant milestone in the fight against cancer. On June 17, the FDA approved… -
FDA Immunotherapy Approvals in 2022
As drug development in cancer immunotherapy has accelerated, the U.S. Food and Drug Administration has made several…
-
Immunotherapy Combination Approved as First-Line Option for Patients with Advanced Triple-Negative Breast Cancer
Patients with advanced triple-negative breast cancer can now receive frontline treatment with immunotherapy in combination with chemotherapy.
-
FDA Approves Pembrolizumab Immunotherapy for Advanced Liver Cancer
Patients with advanced hepatocellular carcinoma (HCC), the most common form of liver cancer, can now receive PD-1…
-
Cemiplimab Becomes First Treatment Approved for Advanced Cutaneous Squamous Cell Carcinoma
Immunotherapy is now approved for patients with advanced forms of the second most common form of skin…
-
First Immunotherapy Approved for Patients with Small Cell Lung Cancer
Nivolumab (Opdivo®) is now available for patients with metastatic and treatment-resistant small cell lung cancer